BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Profectus BioSciences, Inc. Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the “Cure Agenda”


9/17/2013 10:06:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a developer of the next generation of vaccines addressing high-value unmet indications in biodefense, infectious and emerging diseases, announced today the initiation of a phase 1 study evaluating the safety and immunogenicity of a therapeutic HIV vaccine strategy. HIV-infected adults on stable antiretroviral therapy (ART) will receive the Profectus multi-antigen HIV plasmid DNA (MAg-pDNA: env, gag, pol, nef, tat and vif) vaccine administered with the Profectus GENEVAX™ interleukin-12 (IL-12) pDNA adjuvant, delivered using the TriGrid™ electroporation (EP) delivery system licensed from Ichor Medical Systems, as a priming vaccine. This will be followed by booster immunization with the Profectus recombinant vesicular stomatitis virus (rVSV)-vectored HIV vaccine delivered by intramuscular injection. The randomized, double-blind, placebo-controlled study is in support of the HIV Cure Agenda and is being sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The study, which will enroll 30 HIV-infected adults, is being conducted by NIAID’s Dr. Michael Sneller under a protocol designated Theravax 13-I-0141.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES